NUDT21 limits CD19 levels through alternative mRNA polyadenylation in B cell acute lymphoblastic leukemia.

This year's mRNA-Based Therapeutics Summit proved that RNA is a platform, but drug developers must close analytical gaps to see how their constructs work.

The collaboration will combine Wacker Biotech's large-scale, GMP-compliant manufacturing with Eclipsebio's AI-driven RNA design and sequencing-based characterization for best-in-class end-to-end RNA therapeutic development support.

Increasing the scale of IVT presents several challenges, but optimized protocols and comprehensive characterization can lead to a successful mRNA therapeutic.

Lap-in-the-loop platforms like eCOMPASS can help you de-risk potential setbacks in your RNA therapeutic development.